Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.
Dec 7, 2011
0
0
A new potential target to slow breast cancer tumor progression and metastasis has been identified by a team of researchers led by Dr. Richard Kremer from the Research Institute of the McGill University Health Centre (RI-MUHC). ...
Nov 10, 2011
0
0
Mayo Clinic has received investigational new drug approval from the Food and Drug Administration for two new cancer vaccines that mobilize the body's defense mechanisms to destroy malignant cells. The vaccines are among the ...
Aug 17, 2011
0
0
Researchers at Children's Hospital Boston have found a marker called ABCB5 that both tags a small proportion of cells within colorectal cancers and fuels resistance in those cells to standard treatments. The results indicate ...
Jun 8, 2011
0
0
The first results of a multicenter Phase 2 clinical trial on a new brain cancer vaccine tailored to a patient's own tumor will be announced on Monday at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting ...
Jun 6, 2011
0
0
Colorectal cancer patients with defects in mismatch repair--one of the body's systems for repairing DNA damage--have lower recurrence rates and better survival rates than patients without such defects, according to a study ...
May 19, 2011
0
0
Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body's immune system that can predict a breast cancer patients' risk of cancer recurrence. This breakthrough ...
May 16, 2011
0
0
The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Apr 23, 2024
0
0
A new research paper titled "Association between tumor mutations and meningioma recurrence in Grade I/II disease" has been published in Oncoscience.
Jan 17, 2023
0
1
Patient-reported outcome (PRO) data indicates that partial breast irradiation (PBI) is more convenient than whole breast irradiation (WBI) for women with breast cancer who do not receive adjuvant chemotherapy. These participants ...
Jun 3, 2019
0
0
